STOCK TITAN

Mesoblast furnishes ASX director interest change and unquoted securities notices

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.

This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.

Positive

  • None.

Negative

  • None.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of October 2025
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(
Jurisdiction of incorporation or organization)

Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F Form 40-F





INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On October 28, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
On October 28, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited
/s/ Niva Sivakumar
Niva Sivakumar
Company Secretary
Dated: October 29, 2025



INDEX TO EXHIBITS
Item
 99.1
Appendix 3Y of Mesoblast Ltd, dated October 28, 2025.
 99.2
Appendix 3G of Mesoblast Ltd, dated October 28, 2025.




FAQ

What did Mesoblast (MESO) file on Form 6-K?

Mesoblast filed a Form 6-K that furnishes two ASX announcements: Appendix 3Y and Appendix 3G, both dated October 28, 2025, as Exhibits 99.1 and 99.2.

What is included in Exhibit 99.1 for MESO?

Exhibit 99.1 is an Appendix 3Y, a change of director’s interest notice filed with the ASX on October 28, 2025.

What is included in Exhibit 99.2 for MESO?

Exhibit 99.2 is an Appendix 3G, a notification of issue, conversion or payment up of unquoted equity securities filed with the ASX on October 28, 2025.

Why did Mesoblast (MESO) submit these ASX documents via Form 6-K?

The Form 6-K incorporates the ASX filings by reference to make the disclosures available to U.S. investors under the Exchange Act.

Does the Form 6-K disclose financial results for MESO?

No. The Form 6-K furnishes administrative ASX notices (Appendix 3Y and 3G); it does not include earnings data.

When was the Form 6-K dated?

The signature page is dated October 29, 2025.
Mesoblast

NASDAQ:MESO

MESO Rankings

MESO Latest News

MESO Latest SEC Filings

MESO Stock Data

2.32B
121.76M
0.09%
2.68%
1.89%
Biotechnology
Healthcare
Link
Australia
Melbourne